| 2025-11-11 |
详情>>
内部人交易：
MILLER MICHAEL PATRICK股份减少20000.00股
|
| 2025-11-06 |
详情>>
股本变动：
变动后总股本5039.11万股
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.35美元,归母净利润1767.30万美元,同比去年增长61.06%
|
| 2025-11-06 |
财报披露：
美东时间 2025-11-06 盘后发布财报
|
| 2025-08-08 |
复牌提示：
2025-08-08 09:30:44 停牌，复牌日期 2025-08-08 09:35:44
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益0.18美元,归母净利润882.90万美元,同比去年增长194.49%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益0.06美元,归母净利润297.40万美元,同比去年增长161.77%
|
| 2025-04-28 |
股东大会：
将于2025-06-11召开股东大会
会议内容 ▼▲
- 1.Elect eight directors to serve for a one-year term. The nominees are Alan H. Auerbach, Alessandra Cesano, Allison Dorval, Michael P. Miller, Jay M. Moyes, Adrian M. Senderowicz, Brian Stuglik, and Troy E. Wilson;
2.Ratify the selection of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2025;
3.Vote on an advisory basis to approve the compensation of our Named Executive Officers as described in the proxy statement (“say-on-pay vote”);
4.Transact such other business as may properly come before the annual meeting.
|
| 2025-02-27 |
详情>>
业绩披露：
2022年年报每股收益0.00美元,归母净利润2000.00美元,同比去年增长100.01%
|
| 2025-02-27 |
详情>>
业绩披露：
2024年年报每股收益0.62美元,归母净利润3027.80万美元,同比去年增长40.23%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益0.23美元,归母净利润1097.30万美元,同比去年增长17.70%
|
| 2024-08-01 |
详情>>
业绩披露：
2024年中报每股收益-0.19美元,归母净利润-934.4万美元,同比去年增长-364.93%
|
| 2024-08-01 |
详情>>
业绩披露：
2023年中报每股收益0.08美元,归母净利润352.70万美元,同比去年增长-40.9%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益-0.1美元,归母净利润-481.5万美元,同比去年增长-443.68%
|
| 2024-04-26 |
股东大会：
将于2024-06-18召开股东大会
会议内容 ▼▲
- 1.Elect eight directors to serve for a one-year term. The nominees are Alan H. Auerbach, Alessandra Cesano, Allison Dorval, Michael P. Miller, Jay M. Moyes, Adrian M. Senderowicz, Brian Stuglik, and Troy E. Wilson;
2.Ratify the selection of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2024;
3.Vote on an advisory basis to approve the compensation of our named executive officers as described in the proxy statement (“say-on-pay vote”);
4.Vote on an advisory basis regarding the frequency of future say-on-pay votes (“frequency vote”);
5.Approve an amendment to increase the number of shares of the Company’s common stock reserved for issuance under the Puma Biotechnology, Inc. 2011 Incentive Award Plan, as amended (the “2011 Plan”) by 3,000,000 shares and to extend the period during which incentive stock options (“ISOs”) may be granted (the “2011 Plan Amendment”);
6.Transact such other business as may properly come before the annual meeting.
|
| 2024-02-29 |
详情>>
业绩披露：
2023年年报每股收益0.46美元,归母净利润2159.10万美元,同比去年增长1079450.00%
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益0.20美元,归母净利润932.30万美元,同比去年增长66.24%
|
| 2023-04-28 |
股东大会：
将于2023-06-13召开股东大会
会议内容 ▼▲
- 1.Elect eight directors to serve for a one-year term. The nominees are Alan H. Auerbach, Alessandra Cesano, Allison Dorval, Michael P. Miller, Jay M. Moyes, Adrian M. Senderowicz, Brian Stuglik, and Troy E. Wilson;
2.Ratify the selection of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2023;
3.Vote on an advisory basis to approve the compensation of our named executive officers as described in the proxy statement (“say-on-pay vote”);
4.Transact such other business as may properly come before the annual meeting.
|
| 2022-04-29 |
股东大会：
将于2022-06-14召开股东大会
会议内容 ▼▲
- 1.Election of seven directors to serve for a one-year term expiring at the 2023 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal. The nominees are Alan H. Auerbach, Allison Dorval, Michael P. Miller, Jay M. Moyes, Adrian M. Senderowicz, Brian Stuglik, and Troy E. Wilson;
2.Ratification of the selection of KPMG LLP (“KPMG”) as our independent registered public accounting firm for the year ending December 31, 2022;
3.Advisory (non-binding) vote to approve the compensation of our named executive officers as described in the proxy statement (“say-on-pay vote”);
4.Such other business as may properly come before the annual meeting or any adjournments or postponements of the annual meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-26 |
股东大会：
将于2021-06-15召开股东大会
会议内容 ▼▲
- 1.Election of seven directors to serve for a one-year term expiring at the 2022 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal. The nominees are Alan H. Auerbach, Ann C. Miller, Michael P. Miller, Jay M. Moyes, Adrian M. Senderowicz, Brian Stuglik, and Troy E. Wilson.
2.Ratification of the selection of KPMG LLP (“KPMG”) as our independent registered public accounting firm for the year ending December 31, 2021.
3.Advisory (non-binding) vote to approve the compensation of our named executive officers as described in the proxy statement (“say-on-pay vote”).
4.Approve an amendment (the “Auerbach Warrant Amendment”) to the terms of the warrant, issued to Alan H. Auerbach, President and Chief Executive Officer of the Company on October 4, 2011, to purchase 2,116,250 shares of the Company’s common stock at $16.00 per share (the “Auerbach Warrant”), to extend the term of the Auerbach Warrant from October 4, 2021 until October 4, 2026.
5.Approve an amendment (the “2011 Plan Amendment”) to the Puma Biotechnology, Inc. 2011 Incentive Award Plan, as amended (the “2011 Plan”) to increase the number of shares of the Company’s common stock reserved for issuance thereunder by 2,000,000 shares.
6.Such other business as may properly come before the annual meeting or any adjournments or postponements of the annual meeting.
|
| 2020-04-27 |
股东大会：
将于2020-06-09召开股东大会
会议内容 ▼▲
- 1.Election of eight directors to serve for a one-year term expiring at the 2021 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal. The nominees are Alan H. Auerbach, Ann C. Miller, Michael P. Miller, Jay M. Moyes, Hugh O’Dowd, Adrian M. Senderowicz, Troy E. Wilson, and Frank E. Zavrl.
2.Ratification of the selection of KPMG LLP (“KPMG”) as our independent registered public accounting firm for the year ending December 31, 2020.
3.Advisory (non-binding) vote to approve the compensation of our named executive officers as described in the proxy statement (“say-on-pay vote”).
4.Such other business as may properly come before the annual meeting or any adjournments or postponements of the annual meeting.
|
| 2019-04-29 |
股东大会：
将于2019-06-10召开股东大会
会议内容 ▼▲
- 1.Elect six directors to serve for a one-year term;
2.Ratify the selection of our independent registered public accounting firm;
3.Vote on an advisory basis to approve the compensation of our named executive officers as described in the proxy statement (“say-on-pay vote”);
4.Transact such other business as may properly come before the annual meeting.
|
| 2018-04-30 |
股东大会：
将于2018-06-12召开股东大会
会议内容 ▼▲
- 1.Election of six directors to serve for a one-year term expiring at the 2019 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier resignation or removal. The nominees are Alan H. Auerbach, Michael P. Miller, Jay M. Moyes, Adrian M. Senderowicz, Troy E. Wilson and Frank E. Zavrl.
2.Ratification of the selection of KPMG LLP (“KPMG”), as our independent registered public accounting firm for the year ending December 31, 2018.
3.Advisory (non-binding) vote to approve the compensation of our named executive officers as described in the proxy statement (“say-on-pay vote”).
4.Advisory (non-binding) vote regarding the frequency of holding future say-on-pay votes (“frequency vote”).
5.Such other business as may properly come before the annual meeting or any adjournments or postponements of the annual meeting.
|
| 2017-04-28 |
股东大会：
将于2017-06-12召开股东大会
会议内容 ▼▲
- 1.Elect five directors to serve for a one-year term;
2.Ratify the selection of our independent registered public accounting firm;
3.Approve an amendment to the Puma Biotechnology, Inc. 2011 Incentive Award Plan to add a limit on compensation payable to non-employee directors;
4.Approve an amendment to the Puma Biotechnology, Inc. 2011 Incentive Award Plan to increase the number of shares of common stock reserved for issuance thereunder by 2,000,000 shares;
5.Transact such other business as may properly come before the annual meeting.
|
| 2016-04-29 |
股东大会：
将于2016-06-13召开股东大会
会议内容 ▼▲
- 1.Elect five directors to serve for a one-year term;
2.Ratify the selection of our independent registered public accounting firm;
3.Approve an amendment to Puma Biotechnology, Inc.’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to eliminate the ability of stockholders to act by written consent;
4.Approve an amendment to the Certificate of Incorporation to eliminate the mandatory indemnification of all persons covered by Section 145 of the General Corporation Law of the State of Delaware;
5.Transact such other business as may properly come before the annual meeting.
|